Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.41 |
| ▸ | STAMBP | O95630 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965095 | 0.86 | MAPT (0.48) | STAMBPKMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL5070931 | 0.82 | STAMBP (0.44) | STAMBPKMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL1509146 | 0.79 | EGLN1 (0.49) | STAMBPKMT2AMEN1EGLN1L3MBTL1 | |
| SCHEMBL8786558 | 0.78 | SMPD1 (0.42) | SMPD1STAMBPCNR2KMT2AMEN1 | |
| SCHEMBL8883714 | 0.76 | MEN1 (0.50) | SMPD1CNR2KMT2AMEN1EGLN1 | |
| SCHEMBL8881979 | 0.76 | MEN1 (0.50) | SMPD1CNR2KMT2AMEN1EGLN1 | |
| SCHEMBL8880594 | 0.76 | MEN1 (0.50) | SMPD1CNR2KMT2AMEN1EGLN1 | |
| SCHEMBL8882701 | 0.76 | MEN1 (0.50) | SMPD1CNR2KMT2AMEN1EGLN1 | |
| SCHEMBL8784539 | 0.76 | GAA (0.45) | STAMBPCNR2KMT2AMEN1MAPT | |
| SCHEMBL966853 | 0.75 | KMT2A (0.53) | SMPD1CNR2KMT2AMEN1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | SMPD1 1407/4885STAMBP 2533/4885CNR2 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.